Gerresheimer AG : Q1 review – Strong start to 2023, upside risk for guidance
>Strong momentum on top line as expected - The company reported Q1 revenues of € 457.8m (+22.8% y-o-y), which were in line with our forecast, but 4% ahead of the consensus. Organic growth was 21.0% and around 1 percentage point ahead of expectations. Primary packaging glass grew organically by 21.6% in the quarter, while Plastics & devices was up by 20.0%. The Advanced technologies division generated revenues of € 3.4m, higher than expected but from a very low level.§...Gerresheimer is a holding company. Through its subsidiaries, Co. manufactures glass and plastic products for the pharma and healthcare industry. Co.'s operates in three divisions: Plastics & Devices, which its product portfolio includes products for the administration of medicines, such as insulin pens, inhalers, and prefillable syringes; Primary Packaging Glass, which produces glass primary packaging for medicines and cosmetics, such as pharma jars, ampoules, injection vials, cartridges, perfume flacons, and cream jars; and Life Science Research, which produces laboratory glassware for research, development, and analytics, such as beakers, Erlenmeyer flasks, and measuring cylinders.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.